References
Phillips-Howard P, ter Kuile FO. CNS adverse events associated with antimalarial agents. Drug Saf 1995 Jun; 12(6): 370–83
Nosten F, Price RN. New antimalarials: a risk-benefit analysis. Drug Saf 1995 Apr; 12(4): 264–73
Luzzi GA, Peto TEA. Adverse effects of antimalarials: an update. Drug Saf 1993 Apr; 8(4): 295–311
Minimising the adverse effects of antimalarials. Drug Ther Perspect 1993 Sep l3; 2(5): 14–16
Fish DR, Espir MLE. Convulsions associated with prophylactic anti-malarial drugs: implications for people with epilepsy. BMJ 1988 Aug 20–27; 297: 525–7
Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet 1993 May 22; 341: 1299–303
Akhtar S, Mukherjee S. Chloroquine induced mania. Int J Psychiatry Med 1993; 23: 349–56
Bern JL, Kerr L, Stuerchler D. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 1992 Jun; 95: 167–79
Weinke T, Trautmann M, Held T, et al. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 1991; 45(1): 86–91
Cook GC. Adverse effects of chemotherapeutic agents used in tropical medicine. Drug Saf 1995 Jul; 13(1): 31–45
British National Formulary No. 29. London: The Pharmaceutical Press, 1995; 258-65
Rights and permissions
About this article
Cite this article
CNS adverse events with antimalarial drugs — assess the risk:benefit ratio individually. Drugs Ther. Perspect 6, 11–13 (1995). https://doi.org/10.2165/00042310-199506070-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199506070-00005